Estimation of treatment benefits when PSA screening for prostate cancer is discontinued at different ages

Urology

Volumn 66, Issue 5, 2005, Pages 1038-1042

  Ross, Kevin S ^b   Guess, Harry A ^b   Carter, H Ballentine ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; CANCER THERAPY; COMPARATIVE STUDY; DISEASE SIMULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; PATIENT COUNSELING; POPULATION; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME;

AGE FACTORS; AGED, 80 AND OVER; HISTORY, 18TH CENTURY; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MONTE CARLO METHOD; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 27744558577     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2005.05.030     Document Type: Article

References (14)

1. B.E. Sirovich, L.M. Schwartz, S. Woloshin Screening men for prostate and colorectal cancer in the United States does practice reflect the evidence? JAMA 289 2003 1414 1420
2. R. Etzioni, D.F. Penson, J.M. Legler Overdiagnosis due to prostate-specific antigen screening lessons from U.S. prostate cancer incidence trends J Natl Cancer Inst 94 2002 981 990
3. G. Draisma, R. Boer, S.J. Otto Lead times and overdetection due to prostate-specific antigen screening estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95 2003 868 878
4. G. Lu-Yao, T.A. Stukel, S.L. Yao Prostate-specific antigen screening in elderly men J Natl Cancer Inst 95 2003 1792 1797
5. M.R. Cooperberg, G.D. Grossfeld, D.P. Lubeck National practice patterns and time trends in androgen ablation for localized prostate cancer J Natl Cancer Inst 95 2003 981 989
6. P.C. Albertsen, J.A. Hanley, D.F. Gleason Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer JAMA 280 1998 975 980
7. K.S. Ross, H.B. Carter, J.D. Pearson Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection JAMA 284 2000 1399 1404
8. Available: at: www.census.gov. Accessed August 28, 2004.
9. L. Holmberg, A. Bill-Axelson, F. Helgesen Scandinavian Prostatic Cancer Group Study Number 4 a randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer N Engl J Med 347 2002 781 789
10. M. Tornblom, H. Eriksson, S. Franzen Lead time associated with screening for prostate cancer Int J Cancer 108 2004 122 129
11. Available: at: www.cdc.gov/nchs/products/pubs/pubd/lftbls/lftbls.htm. Accessed August 28, 2004.
12. M. McGregor, J.A. Hanley, J.F. Boivin Screening for prostate cancer estimating the magnitude of overdetection Can Med Assoc J 159 1998 1368 1372
13. K.L. Schwartz, S.M. Alibhai, G. Tomlinson Continued undertreatment of older men with localized prostate cancer Urology 62 2003 860 865
14. L.M. Schwartz, S. Woloshin, F.J. Fowler Jr Enthusiasm for cancer screening in the United States JAMA 291 2004 71 78